In Silico Evaluation of a Promising Key Intermediate Thieno [2,3-d] Pyrimidine Derivative with Expected JAK2 Kinase Inhibitory Activity
Molbank · 09.03.2022 · 2022 (1) · M1352
DOI: 10.3390/m1352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molbank, online erschienen am 09.03.2022. Verfasst von Elshaymaa Elmongy und 1 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This work describes the synthesis and the cytotoxic evaluation of thiophene and thienopyrimidine derivatives. The investigated compound was subjected to target prediction that indicated its high affinity to kinases and to Janus kinase 2 (JAK2) specifically. Molecular docking screening was performed on three different JAK2 proteins downloaded from the Protein Data Bank (PDB: 5AEP, 4C62 and 3ZMM). In vitro kinase inhibitory activity was evaluated and then compound cytotoxicity was performed on three different cancerous cell lines (HT-29, HepG-2, and MCF-7). Marked cytotoxic activity of the thienopyrimidine derivative against the HepG-2 cell line was demonstrated, reflected by its IC50 value of 8.001 ± 0.0445 μM, which is better than that of the reference standard (IC50 13.91 ± 2.170 μM). Pharmacokinetic studies revealed good well permeability and GI absorption with no violations against Lipinski’s rule.
Zitieren
APA
Elmongy, E., & Henidi, H. (2022). In Silico Evaluation of a Promising Key Intermediate Thieno [2,3-d] Pyrimidine Derivative with Expected JAK2 Kinase Inhibitory Activity. Molbank, 2022(1), M1352. https://doi.org/10.3390/m1352
Vancouver
Elmongy E, Henidi H. In Silico Evaluation of a Promising Key Intermediate Thieno [2,3-d] Pyrimidine Derivative with Expected JAK2 Kinase Inhibitory Activity. Molbank. 2022;2022(1):M1352. doi:10.3390/m1352
BibTeX
@article{Elmongy2022,
author = {Elmongy, Elshaymaa and Henidi, Hanan},
title = {In Silico Evaluation of a Promising Key Intermediate Thieno [2,3-d] Pyrimidine Derivative with Expected JAK2 Kinase Inhibitory Activity},
journal = {Molbank},
year = {2022},
volume = {2022},
number = {1},
pages = {M1352},
doi = {10.3390/m1352}
}
EUVIMED